Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514963-24-00

Acronym

EMN19

Enrollment

Registered

2024-09-16

Start date

2020-02-04

Completion date

Unknown

Last updated

2025-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma patients presenting with extramedullary disease

Brief summary

Proportion of patients with CR

Detailed description

Duration of Response (DoR), Progression Free Survival (PFS), Overall Response Rate (ORR), Time To next Therapy (TnT), Overall Survival (OS), Safety (adverse events)

Interventions

DRUGDARZALEX 1800 mg solution for injection

DRUGDEXAMETHASONE

DRUGVELCADE 3.5 mg powder for solution for injection

DRUGCYCLOPHOSPHAMIDE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of patients with CR	—

Secondary

Measure	Time frame
Duration of Response (DoR), Progression Free Survival (PFS), Overall Response Rate (ORR), Time To next Therapy (TnT), Overall Survival (OS), Safety (adverse events)	—

Countries

Greece, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026